Reporting their findings in the journal Science, the international team, led by researchers at the University of Kentucky in Lexington, say because of a previously undiscovered property, the drugs may also be effective against other inflammatory disorders.
In their new study on mice with a condition similar to dry AMD, Prof. Ambati and colleagues show that several FDA-approved NRTIs stopped retinal degeneration. But they were surprised to find it was a previously unknown property of the drugs that produced the results.
They found the NRTIs blocked a type of inflammasome called NLRP3. Inflammasomes are large complexes of proteins that play a key role in innate immunity. They detect and respond to certain molecular patterns of pathogens and other damaging agents.
For more info: http://www.medicalnewstoday.com/articles/285865.php